allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded a

Allogene Therapeutics, Inc. Common Stock

Sold all ALLO

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Andrew Drauschak

Mike Pelech

New position in ALLO

Bought 6% more ALLO

Laura Hansen

Bought 5% more ALLO

Bought 25% more ALLO

Bought 27% more ALLO

Sold 50% of ALLO

Patrick Eddings

Zachary Rapp

Bought 43% more ALLO

Bought 70% more ALLO

Bought 100% more ALLO